A phase I expansion study of pegargiminase, cisplatin, and pemetrexed in argininosuccinate synthetase 1-negative recurrent high grade gliomas (HGGs).

Peter E. Hall(Barts Health NHS Trust), Peter W. Szlosarek(St Bartholomew's Hospital), Simon Pacey(Royal Marsden NHS Foundation Trust), Bor-Wen Wu(Polaris (United States)), Matthew Williams(Charing Cross Hospital), Nelofer Syed(Hammersmith Hospital), Fiona Harris(Cambridge University Hospitals NHS Foundation Trust), Timothy Crook(Royal Surrey County Hospital), Stephen Ellis(Barts Health NHS Trust), Richard Shaffer(Bupa Cromwell Hospital), Michael Sheaff(Moorfields Eye Hospital NHS Foundation Trust), Ramsay S. Khadeir(Queen Mary University of London), Xiaoxing Feng(Polaris (United States)), Amanda Johnston(Polaris (United States)), Jane Evanson(Barts Health NHS Trust), Rachel Lewis(St Bartholomew's Hospital), J. A. Thomson, Nick Plowman(Queen Mary University of London), John S. Bomalaski(Polaris (United States))
Journal of Clinical Oncology
May 20, 2018
Cited by 0


Related Papers